Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
Merger and acquisition activity is soaring. Find out why this is the case and how investors can tackle this market with the merger arbitrage strategy in ETF form.
Shares of CR Bard (BCR), also known as Bard, rallied to a new 52-week high of $309.16 on May 12. Let us take a look at the key catalysts driving the stock's performance.
CR Bard Inc. (BCR) is scheduled to report first-quarter 2017 earnings, after market close on Apr 26.
Delving deeper into the fundamentals of C.R. Bard (BCR), let's see how things are shaping up prior to this quarter.
Vanguard Strategic Equity Investor Fund (VSEQX) seeks long-term capital growth by investing primarily in the stocks of small and midsize companies
CR Bard Inc. (BCR) has been struggling lately, but the selling pressure may be coming to an end soon.
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.64 in the third quarter of 2016, exceeding the Zacks Consensus Estimate by 9 cents and also improving 15.8% from the year-ago quarter.
CR Bard Inc. (BCR) is scheduled to report third-quarter 2016 earnings on Oct 25.
CR Bard Inc. (BCR) recently announced the receipt of an Investigational Device Exemption (IDE) approval from the U.S. FDA for its Lutonix 014 Drug Coated Balloon (DCB) to extend the primary endpoint of the product to a 6-month time frame.
CONMED Corporation (CNMD) reported second-quarter 2016 adjusted earnings of 47 cents per share, surpassing the Zacks Consensus Estimate.
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
We expect Varian Medical Systems Inc. to beat earnings when it reports third-quarter 2016 results on Jul 27.
On Jul 7, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).
CR Bard had a robust performance in international markets, extensive expenditure on product innovation and a diversified product portfolio.
Shares of CR Bard (BCR) rallied to a new 52-week high of $232.77 on Jun 29.
On Jun 20, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).